Home / Expertise / Life Sciences & Healthcare
side view of scientist looking into microscope in bright research lab

Life Sciences & Healthcare

Belgium

With over 150 international specialist lawyers across CMS and the support of the Lifesciences Asia-Pacific Network (LAN), we understand the scientific and commercial as well as the legal imperatives affecting your lifesciences business. We work with and have established long-term relationships with the top 100 lifesciences companies in the areas of pharmaceuticals, medical devices, biotechnology, agriculture and food.

Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology, medical devices and diagnostics. As members and partners of major industry associations such as the ABPI, ABHI, BIVDA, PAGB, EFPIA and EUCOMED we help shape the legal frameworks impacting the lifesciences sector. 

We regularly advise our clients on their day-to-day operational needs such as, patent enforcement, commercial and clinical trial agreements, protection of privacy and trade secrets, e-health, support with advertisement and promotion of medicine, public sector procurement, pricing and reimbursement as well as regulatory advice. 

Equally, when you need lifesciences specialist advice for strategic agreements, planning a corporate transaction or embarking on litigation (whether product liability or otherwise), we have a team that is well versed in the industry issues to help you.

Read more Read less
Lifes­ci­ences & Health­care
September 2019
CMS Life Sci­ences & Health­care Glob­al Bro­chure

Feed

Show only
September 2019
CMS Life Sci­ences & Health­care Glob­al Bro­chure
15 Nov 19
Brexit and data pro­tec­tion: what to do next (when you don’t know what’s...
Whilst the threat of a no-deal Brexit has been aver­ted for now, the fu­ture is by no means cer­tain. We have high­lighted some of the key is­sues for UK-based or­gan­isa­tions, and the EEA or­gan­isa­tions that...
22/03/2019
Voors­chriften mo­eten elektron­isch zijn vanaf 1 janu­ari...
05 Nov 19
Whis­tleblow­ing Dir­ect­ive ad­op­ted by the EU Coun­cil
On 7 Oc­to­ber 2019, the EU Coun­cil ap­proved the word­ing of the "Dir­ect­ive of the European Par­lia­ment and of the Coun­cil on the pro­tec­tion of per­sons who re­port breaches of Uni­on law", also known as the...
30/11/2018
Novem­ber 2018 News­let­ter
13 Sep 19
SPC Double Whammy - In­ter­pret­ing Art­icle 3(a) of the SPC Reg­u­la­tion
Sum­mary At the end of June, the CJEU heard the joint re­fer­rals from the Ger­man Bundes­pat­ent­gericht (case C-650/17) for Mer­ck’s sitaglipt­in product and from the Eng­lish Court of Ap­peal for Searle’s...
November 2018
NGOS CAN ASK THE COM­MIS­SION TO RE­VIEW ITS DE­CISION...
BIO-SCI­ENCE LAW RE­VIEW - VOL 16 IS­SUE 6 BSLR : CASE...
18 Jun 19
The Bel­gian Com­pet­i­tion Au­thor­ity con­demns the Or­der of Phar­macists...
On 28 May 2019, the Bel­gian Com­pet­i­tion Au­thor­ity ruled that the Or­der of Phar­macists had used its in­flu­ence to hinder the busi­ness activ­it­ies of the in­nov­at­ive phar­macy and paraphar­macy chain Medi­Care-Mar­ket. ...
16/03/2018
March 2018 News­let­ter
13 Jun 19
SPC Man­u­fac­tur­ing Waiver to come in­to ef­fect 1 Ju­ly 2019
Gen­er­ics com­pan­ies will soon be able to man­u­fac­ture SPC-pro­tec­ted drugs for ex­port out­side the EU un­der new man­u­fac­tur­ing waiver pro­vi­sions. In the last six months of the SPC life­time, it will also be...
31/01/2018
Janu­ary 2018 News­let­ter
30 May 19
EPO's strict ap­proach to de­cid­ing if a com­pos­i­tion can be­ne­fit from...
The EPO Tech­nic­al Board of Ap­peal (TBA) re­viewed the law around nov­elty of use, and de­term­ined that in the case of Car­di­oPoly­mer, Inc.'s European pat­ent ap­plic­a­tion (EP07837908.8), the claimed chem­ic­al...